Moleculin Biotech Stock Is Sinking Friday: What's Going On?
Moleculin Biotech updates MIRACLE trial for AML and prices a $9.3M offering at $0.75, driving MBRX shares down 63%. Read full data.
Moleculin Biotech announced a trial update and raised money by selling new shares at a low price, which made existing shareholders' pieces worth less. When a company sells lots of new shares cheaply, it can signal the stock was already struggling, so watch how the company uses that money.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.